January 2026 SCRI Release Notes Copied
SCRI Trials and Trial Regimen Updates
The following updates were completed between December 12, 2025, and January 20, 2026. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens.
For questions about these trials and regimens, please contact SCRIiKMEMRedits@McKesson.com.
New Builds Completed
| Study Number | Notes for New Build |
| 25113 | USOR 25113 BRE 474 Phase 3 Palazestrant or Placebo + Letrozole or Placebo + Ribociclib Q28D – v1.0 12Jun2025 |
| 25075 | USOR 25075 GI 417 Phase 2 BMS-986504 or Placebo (400 mg) + Nab-paclitaxel + Gemcitabine Q28D – 24JUN2025
USOR 25075 GI 417 Phase 2 BMS-986504 or Placebo (600 mg) + Nab-paclitaxel + Gemcitabine Q28D – 24JUN2025 |
| 25030 | USOR 25030 CLL 67 Phase 3 Arm A BGB-16673 Q28D – 13AUG2025
USOR 25030 CLL 67 Phase 3 Arm B Bendamustine + Rituximab Q28D – 13AUG2025 USOR 25030 CLL 67 Phase 3 Arm B Idelalisib + Rituximab Q28D – 13AUG2025 USOR 25030 CLL 67 Phase 3 Arm B Venetoclax + Rituximab Q28D – 13AUG2025 USOR 25030 CLL 67 Phase 3 Arm B Venetoclax Ramp-Up – 13AUG2025 |
| 24302 | USOR 24302 GI 404 Phase 2 Arm A ONO-4578 + Opdivo + Bevacizumab + mFOLFOX6 Q28D – v3.0 20MAR2025
USOR 24302 GI 404 Phase 2 Arm B ONO-4578 + Opdivo + Bevacizumab + mFOLFOX6 Q28D – v3.0 20MAR2025 USOR 24302 GI 404 Phase 2 Arm C Bevacizumab + mFOLFOX6 Q28D – v3.0 20MAR2025 |
| 25007 | USOR 25007 BRE 462 Phase 3 Arm 1 HER3-DXd Q84D – 25APR2025
USOR 25007 BRE 462 Phase 3 Arm 2 Capecitabine Q84D – 25APR2025 USOR 25007 BRE 462 Phase 3 Arm 2 Liposomal Doxorubicin Q84D – 25APR2025 USOR 25007 BRE 462 Phase 3 Arm 2 Nab-paclitaxel Q84D – 25APR2025 USOR 25007 BRE 462 Phase 3 Arm 2 Paclitaxel (80 mg/m2) Q84D – 25APR2025 USOR 25007 BRE 462 Phase 3 Arm 2 Paclitaxel (90 mg/m2) Q84D – 25APR2025 USOR 25007 BRE 462 Phase 3 Arm 2 T-DXd Q84D – 25APR2025 |
| 25131 | USOR 25131 CML 30 Phase 3b Asciminib Q84D – v03 17MAY2024 |
| 24293 | USOR 24293 GU 268 Phase 3 AAA817 + ARPI Q56D – v00 17JAN2025
USOR 24293 GU 268 Phase 3 AAA817 Q56D – v00 17JAN2025 USOR 24293 GU 268 Phase 3 ARPI Q56D – v00 17JAN2025 USOR 24293 GU 268 Phase 3 Cabazitaxel Q21D – v00 17JAN2025 USOR 24293 GU 268 Phase 3 Docetaxel Q21D – v00 17JAN2025 |
| LUN 537 (ILCC) |
LUN 537 Phase 3 V940 or Placebo + Pembrolizumab Q42D – 14Aug2025 |
| 25004 | USOR 25004 AML 81 Phase 3 Intensive Therapy Consolidation Ziftomenib or Placebo + Cytarabine Q28D – 15AUG2025
USOR 25004 AML 81 Phase 3 Intensive Therapy Induction Ziftomenib or Placebo + Cytarabine + Daunorubicin Q28D – 15AUG2025 USOR 25004 AML 81 Phase 3 Maintenance Ziftomenib or Placebo Q28D – 15AUG2025 USOR 25004 AML 81 Phase 3 Nonintensive Therapy Ziftomenib or Placebo + Venetoclax + Azacitidine Q28D – 15AUG2025 |
| 25114 | USOR 25114 GYN 162 Phase 2 INCB123667 Q28D – v3 15AUG2025 |
| 24221 | USOR 24221 CH 03 Phase 3 Mavorixafor (X4P-001) or Placebo Q52W |
| 25009 | USOR 25009 LYM 256 Phase 2 Bridging Therapy (Placeholder) – v6.0 11MAR2025
USOR 25009 LYM 256 Phase 2 Cyclophosphamide + Fludarabine D-5,-4,-3 – v6.0 11MAR2025 USOR 25009 LYM 256 Phase 2 LYL314 D0 – v6.0 11MAR2025 |
| 25110 | USOR 25110 GYN 161 Phase 2 Substudy 1 Bevacizumab Q21D – v3.0 22AUG2025
USOR 25110 GYN 161 Phase 2 Substudy 1 Mirvetuximab soravtansine + Bevacizumab Q21D – v3.0 22AUG2025 USOR 25110 GYN 161 Phase 2 Substudy 2 Mirvetuximab soravtansine + Carboplatin Q21D – v3.0 22AUG2025 |
| 25086 | USOR 25086 RM 1145 Phase 1b GSK5764227 Q21D – 05MAR2025 |
| 25021 | USOR 25021 BRE 466 Phase 3 Arm A PF-07248144 + Fulvestrant Q28D – 07APR2025
USOR 25021 BRE 466 Phase 3 Arm B Everolimus + Exemestane Q28D – 07APR2025 USOR 25021 BRE 466 Phase 3 Arm B Everolimus + Fulvestrant Q28D – 07APR2025 |
| 25154 | USOR 25154 GI 428 Phase 2 Pumitamig or Bevacizumab + FOLFIRI Q14D – 09Oct2025
USOR 25154 GI 428 Phase 2 Pumitamig or Bevacizumab + FOLFOX Q14D – 09Oct2025 |
| 25173 | USOR 25173 LUN 650 Phase 2 PF-08634404 + Carboplatin + Etoposide Q21D fb PF-08634404 Q21D – 06Nov2025 |
| 25174 | USOR 25174 LUN 651 Phase 1b Part A PF-08634404 + Sigvotatug Vedotin Q42D – 23Oct2025
USOR 25174 LUN 651 Phase 1b Part B PF-08634404 + PF-08046054 Q21D – 23Oct2025 |
| 25139 | USOR 25139 BRE 475 Phase 3 Part 1 Cohort 1 LY4064809 + Palbociclib + ET Q28D – 08Sep2025 |
| 25156 | USOR 25156 LUN 645 Phase 3 Part 1 PF-08634404 or Placebo + Pembrolizumab or Placebo + Nab-paclitaxel + Carboplatin Q21D fb PF-08634404 or Placebo + Pembrolizumab or Placebo Q21D – 05Nov2025
USOR 25156 LUN 645 Phase 3 Part 1 PF-08634404 or Placebo + Pembrolizumab or Placebo + Paclitaxel + Carboplatin Q21D fb PF-08634404 or Placebo + Pembrolizumab or Placebo Q21D – 05Nov2025 USOR 25156 LUN 645 Phase 3 Part 2 PF-08634404 or Placebo + Pembrolizumab or Placebo + Pemetrexed + Carboplatin Q21D fb PF-08634404 or Placebo + Pembrolizumab or Placebo + Pemetrexed Q21D – 05Nov2025 |
| 24031 | USOR 24031 GU 251 Phase 3 AAA817 Q56D – 18JUN2025
USOR 24031 GU 251 Phase 3 Standard of Care (Placeholder) – 18JUN2025 |
| 24325 | USOR 24325 BRE 465 Phase 2 Arm A (1 or 2) Izalontamab Brengitecan Q21D – 30APR2025
USOR 24325 BRE 465 Phase 2 Arm B Capecitabine Q21D – 30APR2025 USOR 24325 BRE 465 Phase 2 Arm B Gemcitabine + Carboplatin Q21D – 30APR2025 USOR 24325 BRE 465 Phase 2 Arm B Nab-Paclitaxel Q28D – 30APR2025 USOR 24325 BRE 465 Phase 2 Arm B Paclitaxel Q28D – 30APR2025 |
| 24289 | USOR 24289 LUN 589 Phase 3 Olomorasib or Placebo Q28D – 27JUN2025
USOR 24289 LUN 589 Phase 3 Part A Olomorasib or Placebo + Pembrolizumab Q21D – 27JUN2025 USOR 24289 LUN 589 Phase 3 Part B Olomorasib or Placebo + Durvalumab Q28D – 27JUN2025 |
| 24110 | USOR 24110 LUN 605 Phase 2 Adjuvant Pembrolizumab Q21D – 03JUL2025
USOR 24110 LUN 605 Phase 2 Arm 1 Neoadjuvant Pembrolizumab + Gemcitabine + Carboplatin Q21D – 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 1 Neoadjuvant Pembrolizumab + Gemcitabine + Cisplatin Q21D – 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 1 Neoadjuvant Pembrolizumab + Paclitaxel + Carboplatin Q21D – 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 1 Neoadjuvant Pembrolizumab + Paclitaxel + Cisplatin Q21D – 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 1 Neoadjuvant Pembrolizumab + Pemetrexed + Carboplatin Q21D – 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 1 Neoadjuvant Pembrolizumab + Pemetrexed + Cisplatin Q21D – 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 2 Adjuvant Gemcitabine + Carboplatin Q21D – 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 2 Adjuvant Gemcitabine + Cisplatin Q21D – 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 2 Adjuvant Paclitaxel + Carboplatin Q21D – 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 2 Adjuvant Pemetrexed + Carboplatin Q21D – 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 2 Adjuvant Pemetrexed + Cisplatin Q21D – 03JUL2025 USOR 24110 LUN 605 Phase 2 Arm 2 Neoadjuvant sac-TMT + Pembrolizumab Q21D – 03JUL2025 |
| 25070 | USOR 25070 LUN 535 Phase 1b BBO-8520 + Pembrolizumab Q21D – v5.0 03SEP2025
USOR 25070 LUN 535 Phase 1b BBO-8520 Q21D – v5.0 03SEP2025 |
| 24270 | USOR 24270 MDS 36 Phase 3 Azacitidine Q28D – v2.0 19SEP2024
USOR 24270 MDS 36 Phase 3 Ivosidenib Q28D – v2.0 19SEP2024 |
| 25116 | USOR 25116 HN 43 Phase 3 Arm A Pembrolizumab + Carboplatin + Amivantamab Q21D – 23Jul2025
USOR 25116 HN 43 Phase 3 Arm B Pembrolizumab + Carboplatin + Fluorouracil Q21D – 23Jul2025 USOR 25116 HN 43 Phase 3 Arm B Pembrolizumab + Cisplatin + Fluorouracil Q21D – 23Jul2025 |
Updated Reference Information
| Study Number | Updated Reference Information | Updated Drug Service Order Information | Updated Regimen Instructions | Other Changes |
| 23094 | PA10: 11 Apr 2025 (sponsor decision to hold pa9) | N/A | Regimen comments; Admin | Update drug; instructions |
| 23095 | PAv5.0: 30 Jul 2025 | N/A | N/A | Update drug; instructions |
| 24093 | Memo: 03 Oct 25 | N/A | N/A | Update drug; instructions |
| 24094 | Site Edits: IPC Dispensation update | N/A | N/A | Update drug; frequency |
| 24234 | PA 3.0; 04 August 2025 | N/A | N/A | Update drug; instructions |
| 22201 | Update Drug Form to AIBW | N/A | N/A | Update drug; dose/form |
| 24310 | Memo; 08 Sept 2025 | N/A | N/A | Update drug; dose/form |
| 24267 | PM v5.0; 10th December 2025 | N/A | N/A | Update drug; instructions, name |
| 23284 | PA 3.0, 18 June 2025 | N/A | Regimen comments; prophylaxis, observation | Update drug; procurement |
| 23289 | Version 3.3; 5th August 2025 | N/A | N/A | Update drug; instructions |
| 24149 | Version 4.0; 08 Sept 2025; V3.0;29Jul2025 | N/A | Regimen comments; admin, premedication | Update drug; instructions |
| 25018 | Version 4.1; 24th November 2025 | N/A | N/A | Update drug; instructions |
| 24043 | PA v3.0; 29 July 2025 | N/A | Regimen comments; Admin | Update drug; premedication |
| 24196 | Version 3.0; 26 March 2025 | N/A | Regimen comments; admin, prophylaxis, premedication | N/A |
| 24070 | Version 2.0; 05 November 2025 – PM v3.0; 06NOV2025 | N/A | Regimen comments; Observation | Update drug; dose/form, instruction |
| 24070 | DIL; 21 November 2025 | N/A | N/A | Update drug; instructions |
| 24070 | Memo; 18 November 2025 | N/A | N/A | Update drug; instructions |
| 24144 | PM v8.0: 15 Oct 2025 | N/A | N/A | Update drug; name and instructions |
| 24006 | PM v2.1: 09 Dec 2025 | N/A | N/A | Update drug; instructions and name |
| 23107 | Version 5.0; 16 July 2025 | N/A | Regimen comments; admin | Update drug; instructions |
| 21270 | PA v9.0: 03 Nov 2025 | N/A | Regimen comments; premedication | Update drug; instructions |
| 23234 | PA v3.0; 13 May 2025 | N/A | Regimen comments; admin, premedication | Update drug; admin/prep, instructions |
| 23240 | Version 8.0; 17 Sept 2025 | N/A | Regimen comments; admin | Update drug; instructions |
| 23085 | PA v4.0; 20 June 2025 | N/A | N/A | Update drug; instructions.
Added drug. |